Marburg Hemorrhagic Fever - Pipeline Review, H2 2016

  • ID: 3821654
  • Report
  • 77 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • GeoVax Labs, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • NanoViricides, Inc.
  • MORE
Marburg Hemorrhagic Fever - Pipeline Review, H2 2016

Summary

‘Marburg Hemorrhagic Fever - Pipeline Review, H2 2016’, provides an overview of the Marburg Hemorrhagic Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marburg Hemorrhagic Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburg Hemorrhagic Fever and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Marburg Hemorrhagic Fever
- The report reviews pipeline therapeutics for Marburg Hemorrhagic Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Marburg Hemorrhagic Fever therapeutics and enlists all their major and minor projects
- The report assesses Marburg Hemorrhagic Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Marburg Hemorrhagic Fever

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Marburg Hemorrhagic Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Marburg Hemorrhagic Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • GeoVax Labs, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • NanoViricides, Inc.
  • MORE
List of Figures

Introduction

Report Coverage

Marburg Hemorrhagic Fever Overview

Therapeutics Development

Pipeline Products for Marburg Hemorrhagic Fever - Overview

Pipeline Products for Marburg Hemorrhagic Fever - Comparative Analysis

Marburg Hemorrhagic Fever - Therapeutics under Development by Companies

Marburg Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes

Marburg Hemorrhagic Fever - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Marburg Hemorrhagic Fever - Products under Development by Companies

Marburg Hemorrhagic Fever - Products under Investigation by Universities/Institutes

Marburg Hemorrhagic Fever - Companies Involved in Therapeutics Development

Arno Therapeutics, Inc.

BioCryst Pharmaceuticals, Inc.

GeoVax Labs, Inc.

GlaxoSmithKline Plc

Integrated BioTherapeutics, Inc.

Johnson & Johnson

NanoViricides, Inc.

Profectus BioSciences, Inc.

Sarepta Therapeutics, Inc.

Marburg Hemorrhagic Fever - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(Ebola + Marburg) (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Ebola + Marburg) (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Ebola + Marburg) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Ebola [Sudan, Zaire] + Marburg) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

1-E703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies for Ebola and Marburg Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVI-7288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCX-4430 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GOVXE-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GOVXE-302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Marburg vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for Marburg Virus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Glycoprotein for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Marburg Hemorrhagic Fever - Dormant Projects

Marburg Hemorrhagic Fever - Discontinued Products

Marburg Hemorrhagic Fever - Product Development Milestones

Featured News & Press Releases

Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform

Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate

Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease

May 07, 2013: Sarepta Therapeutics Initiates Dosing In Phase I Multiple Ascending Dose Study Of Drug For Treatment Of Marburg Virus

Mar 04, 2013: Sarepta Therapeutics's Marburg Drug Shows High Survival Rates After Intramuscular Delivery In Non-Human Primates

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016

Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Marburg Hemorrhagic Fever - Pipeline by Arno Therapeutics, Inc., H2 2016

Marburg Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2016

Marburg Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H2 2016

Marburg Hemorrhagic Fever - Pipeline by GlaxoSmithKline Plc, H2 2016

Marburg Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2016

Marburg Hemorrhagic Fever - Pipeline by Johnson & Johnson, H2 2016

Marburg Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H2 2016

Marburg Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H2 2016

Marburg Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Marburg Hemorrhagic Fever - Dormant Projects, H2 2016

Marburg Hemorrhagic Fever - Discontinued Products, H2 2016 71List of Figures

Number of Products under Development for Marburg Hemorrhagic Fever, H2 2016

Number of Products under Development for Marburg Hemorrhagic Fever - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Arno Therapeutics, Inc.
BioCryst Pharmaceuticals, Inc.
GeoVax Labs, Inc.
GlaxoSmithKline Plc
Integrated BioTherapeutics, Inc.
Johnson & Johnson
NanoViricides, Inc.
Profectus BioSciences, Inc.
Sarepta Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll